

NASH CRN Published Manuscripts, as of 20 April 2015

2003

Lavine JE, Schwimmer JB for the NASH CRN: Pediatric initiatives within the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). *J Pediatr Gastroenterol Nutr* 2003, 37:220-221.

Nonalcoholic Steatohepatitis Clinical Research Network. *Hepatology* 2003, 37:244.

2005

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y, Torbenson MS, Ünalp A, Yeh M, McCullough AJ, Sanyal AJ, for the Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histologic scoring system for nonalcoholic fatty liver disease (NAFLD). *Hepatology* 2005, 41:1313-1321.

2006

Lavine JE, Schwimmer JB: Clinical research network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children. *J Pediatr Gastroenterol Nutr* 2006, 42:129-130

Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE: Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. *J Pediatr Gastroenterol Nutr* 2006, 43:413-427.

2007

Caldwell SH, Patrie JT, Brunt EM, Redick JA, Davis CA, Park SH, Neuschwander-Tetri BA: The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. *Hepatology* 2007, 46:1101-1107.

Westphalen AC, Qayyum A, Yeh BM, Merriman RB, Lee JA, Lamba A, Lu Y, Coakley FV: Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. *Radiology* 2007, 242:450-455.

2008

Bahl M, Qayyum A, Westphalen AC, Noworolski SM, Chu PW, Ferrell L, Tien PC, Bass NM, Merriman RB: Liver Steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. *Radiology* 2008, 249:160-166.

Bydder M, Yokoo T, Hamilton G, Middleton MS, Chavez AD, Schwimmer JB, Lavine JE, Sirlin CB: Relaxation effects in the quantification of fat using gradient echo imaging. *Magn Reson Imaging* 2008, 26: 347-359. PMID: PMC2386876.

Chalasanani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Ünalp A, for the NASH Clinical Research Network: Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. *Hepatology* 2008, 48:829-834. PMID: PMC2346454.

Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB: Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 2008, 47:1158-1166. PMID: PMC3096839

Neuschwander-Tetri BA, Ünalp A, Creer M, Seeff L: Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. *Arch Intern Med* 2008, 168: 663-666.

Patton H, Lavine J, Van Natta ML, Schwimmer J, Kleiner D, Molleston J, and the Nonalcoholic steatohepatitis Clinical Research Network (NASH CRN): Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis (NASH). *Gastroenterology* 2008,135:1961-1971. PMID: PMC2628583

2009

Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA, and the NASH Clinical Research Network: Portal chronic Inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD - Clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. *Hepatology* 2009; 49: 809-820. PMID: PMC928479

Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Ünalp A, Tonascia J, for the NASH CRN Research Group: Pioglitazone versus Vitamin E versus placebo for the treatment of non-alcoholic patients with nonalcoholic steatohepatitis: PIVENS Trial Design. *Contemp Clin Trials* 2009, 30:88-96. PMID: PMC2929909

David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB, and the NASH CRN Research Group: Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the NASH CRN. *Hepatology* 2009; 49:1904-1912. PMID: PMC2692572

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ: Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. *Hepatology* 2009; 50:1072-1078. PMID: PMC2757511

Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, Patton HM, Lavine JE, and Sirlin CB: Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. *J Magn Reson Imaging* 2009; 30:145-152. PMID: PMC2982807

Shah, AG, Lydecker A, Murray K, Tetri BN, Contos MJ, and Sanyal AJ and the NASH Clinical Research Network: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009;10:1104-1112. PMID: PMC3079239

Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, et al: Diagnostic and fat-grading accuracy of low flip-angle, multi-echo acquisition, gradient-recalled-echo magnetic resonance imaging in non-alcoholic fatty liver disease at 1.5T. *Radiology* 2009 251:67-76. PMID: PMC2663579

2010

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, and Diehl AM for the Nonalcoholic Steatohepatitis Clinical Research Network: Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010; 51: 1961-71.

PMCID: PMC2922495.

Chalasanani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JJ, and the NASH CRN: Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. *Gastroenterology* 2010; 139: 1567-1576. PMCID:PMC2967576.

Kistler KD, Molleston J, Ünalp A, Abrams SH, Behling C, and Schwimmer JB, for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN): Symptoms and quality of life in obese children and adolescents with nonalcoholic fatty liver disease. *Alimentary Pharmacology & Therapeutics* 2010; 31: 396-406. PMCID: PMC2807909.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Ünalp A, Tonascia J, and The NASH CRN Research Group: Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. *Contemporary Clinical Trials* 2010; 31: 62-70. PMCID: PMC2936451.

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasanani N, and Kowdley KV, for the NASH Clinical Research Network: Clinical, laboratory, and histological associations in adults with nonalcoholic fatty liver disease. *Hepatology* 2010; 52; 913-924. PMCID: PMC3070295.

Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang T, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE, and the NASH CRN: Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. *Am J Gastroenterol* 2010; 105: 2093-2102. PMCID: PMC3070291.

Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ and the NASH CRN: The association of genetic variability in PNPLA3 with histological severity of non-alcoholic fatty liver disease. *Hepatology* 2010; 52; 894-903. PMCID: PMC2932770.

Sanyal AJ, Chalasanani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, and Robuck PR, for the NASH CRN: Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. *New Engl J Med* 2010; 362: 1675-85. PMCID: PMC2928471.

Speliotes EK, Butler JL, Palmer CD, Voight BF, the GIANT Consortium, the MIGen Consortium, the NASH CRN, Hirschhorn JN: PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. *Hepatology* 2010; 52: 904-912. PMCID: PMC3070300.

Suzuki A, Abdelmalek MF, Unalp-Arida A, Yates K, Sanyal AJ, Guy CD, Diehl AM: Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology* 2010; 8; 1062-69. PMCID: PMC3089422.

2011

Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA for the NASH Clinical Research Network (CRN): Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the histopathologic

diagnosis in NAFLD: Distinct clinicopathologic meanings. *Hepatology* 2011; 53:810-820. PMID: PMC3079483.

Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD: Centrizonal Arteries and Microvessels in Non-Alcoholic Steatohepatitis. *Am J Surg Path* 2011; 35:1400-1404. PMID: PMC3156381.

Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, et al. SIRT3 Deficiency and Mitochondrial Protein Hyperacetylation Accelerate the Development of the Metabolic Syndrome. *Molecular Cell*. 2011; 44:177-190. PMID: PMC3563434

Kistler KD, Brunt EM, Clark JM, Diel AM, Sallis JF, and Schwimmer JB, for the NASH CRN Research Group: Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. *Am J Gastroenterol* 2011; 106:460-468. PMID: PMC3070294.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al: Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. The TONIC Randomized Controlled Trial. *JAMA* 2011; 305:1659-1668. PMID: PMC3110082.

Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Ünalp-Arida A, Kowdley KV, and the NASH CRN: Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. *Hepatology* 2011; 53:448-457. PMID: PMC3058264.

Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al: Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genetics* 2011; 7(3), e1001324. PMID: PMC3053321.

Tandra S, Yeh MM, Brunt EM, Vuppalanchi R, Cummings OW, Ünalp-Arida A, et al: Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. *Journal of Hepatology* 2011; 55:654-659. PMID: PMC3139780.

Zein CO, Ünalp A, Colvin R, Liu YC, McCullough AJ for the NASH CRN: Smoking and increased severity of hepatic fibrosis in nonalcoholic fatty liver disease. *Journal of Hepatology* 2011; 54: 753-759. PMID: PMC3060962.

2012

Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; for the Nonalcoholic Steatohepatitis Clinical Research Network. Ethnicity and Nonalcoholic Fatty Liver Disease. *Hepatology*. 2012;55:769-780. PMID: PMC3278533

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in NASH: a PIVENS follow-up study. *Hepatology*. 2012; 56: 1311-1318. PMID: PMC3432683

Cheng JF, Joyce A, Yates K, and Sanyal AJ for the NASH CRN: Metabolomic profiling to identify predictors of response to vitamin E for nonalcoholic steatohepatitis (NASH). *PLoS One*. 2012; 7:e44106. doi:10.1371/journal.pone.0044106. PMID: PMC3446974

Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, and Schwimmer JB; for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Modest alcohol consumption

is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD). *Journal of Hepatology*. 2012;57:384-391. PMID: PMC3399018

Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl AM, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. *The American Journal of Clinical Nutrition*. 2012;95:892-900. PMID: PMC3302364

Guy CD, Suzuki A, Burchette HT, Brunt EM, Abdelmalek MF, Cardona D, et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. *Human Pathology*. 2012; 43(6): 790-800. PMID: PMC3288773

Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; for the NASH CRN. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. *Hepatology*. 2012; 55(6): 1711-21. PMID: PMC3499103

Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri B, Chalasani N, et al.; for the NASH Clinical Research Network. Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease. *Hepatology*. 2012;55:77-85. PMID: PMC3245347

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; and the NASH Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology*. 2012;56:943-951. PMID: PMC3407289

Nelson JE, Brunt EM, Kowdley KV; for the NASH Clinical Research Network. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. *Hepatology*. 2012;56:1730-1740. PMID: PMC3462887

Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann A, Unalp-Arida A, et al.; for the NASH CRN. Association between puberty and features of nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*. 2012;10:786-794. PMID: PMC3382041

Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, et al.; on behalf of the NASH CRN Research Group. Correlation of Vitamin E, uric acid, and diet composition with histologic features of pediatric nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr*. 2012;54:90-96. PMID: PMC3208079

Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. *Hepatology International*. 2012; 6: 379-385. PMID: PMC3511661

2013

Chen Q-R, Braun R, Hu Y, Yan C, Brunt E, Meerzaman D, Sanyal A, Buetow K. Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. *PLoS One*. 2013;8(7): e65982. doi:10.1371/journal.pone.0065982. PMID: PMC3716805

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. for the NASH CRN. Vitamin E and changes in serum alanine aminotransferase levels in patients with nonalcoholic steatohepatitis. *Alimentary Pharmacology & Therapeutics*. 2013;38:134-143. PMID: PMC3775262

Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A, for the NASH CRN. Histologic abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. *Journal of Pediatrics*. 2014;164:707-13. PMC3962701

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, et al. for the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. *Hepatology*. 2013;58:1644-1654. PMID: PMC3760979

St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, Lavine JE, for the NASH CRN. Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr*, 2013;57: 627-633. PMID: PMC3864540

Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology*. 2013;267:422-431. PMID: PMC3632805

2014

Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. *PLoS One*. 2014; 9(4):e95366. doi:10.1371/journal.pone.0095366. PMC3997354

Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; for the NASH CRN. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. *Liver International*. 2014;34:1250-1258. PMC4010559

Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A, for the NASH CRN. Histologic abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. *Journal of Pediatrics*. 2014;164:707-13. PMC3962701

Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, Donithan M, Tonascia J, for the NASH CRN. High blood pressure in children and adolescents with nonalcoholic fatty liver disease. *PLoS One*. 2014;9(11): e112569. doi:10.1371/journal.pone.0112569. PMC4242611

Siddique A, Nelson JE, Aouizerat B, Yeh MM, Kowdley KV, for the NASH Clinical Research Network. Iron deficiency in nonalcoholic fatty liver disease is associated with obesity, female sex, elevated serum IL6 and IL1 β levels and decreased serum hepcidin levels. *Clin Gastroenterol Hepatol*. 2014;12:1170-1178. PMC4028425.

2015

Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N, for the NASH CRN. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. *Aliment Pharmacol Ther*. 2015;41:301-309. NIHMSID:NIHMS646618

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N, for the NASH CRN. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr*, 2015;60:360-367. PMC4341955

Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM. Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity. *Hepatology*. 2015;61:98-107. PMC4241186

Hourigan SK, Abrams S, Yates K, Pfeifer K, Torbenson M, Murray K, Roth CL, Kowdley K, Scheimann A, for the NASH CRN. The relationship between vitamin D status and nonalcoholic fatty liver disease in children. *J Pediatr Gastroenterol Nutr*. 2015;60:396-404. PMC4341959

Neuschwander-Tetri B, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, for the NASH CRN. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet*. 2015; 385: 956-965. NIHMSID:NIHMS672595
